



Radicava® (edaravone)

When requesting Radicava® (edaravone injection), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Radicava is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Coverage Guidelines

For the treatment of amyotrophic lateral sclerosis (ALS)

Initial Authorization:

The individual must meet ALL of the following criteria for approval:

- Has a “definite” or “probable” diagnosis of amyotrophic lateral sclerosis (ALS) based on the application of the El Escorial or the revised Airlie House diagnostic criteria
- Has a score of 2 points or more on each item of the ALS Functional Rating Scale – Revised (ALSFRS-R) [i.e., has retained most or all activities of daily living]
- Has a percent-predicted force vital capacity (FVC) greater than or equal to 80% (i.e., has normal respiratory function)
- Has been diagnosed with ALS for ≤2 years
- Has received or is currently receiving riluzole tablets (Rilutek®, generics), Tiglutik® (riluzole oral suspension), or Exservan (riluzole oral film).
- Radicava is prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS

Re-authorization:

The individual must meet ALL of the following criteria for approval:

- Continues to benefit from Radicava therapy
- Does not require invasive ventilation
- Radicava is prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS

Approval duration (initial & renewal): 6 months

Recommended Dosing

The recommended dose of Radicava is 60 mg administered as an intravenous infusion over 60 minutes as follows:

- Initial treatment cycle: daily dosing for 14 days followed by a 14-day drug-free period

Subsequent treatment cycles: daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods

References

1. Radicava™ injection [prescribing information]. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation; August 2018.
2. Petroliv D, Mansfield C, Moussy A, et al. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? *Front Aging Neurosci.* 2017;9:68.
3. Salameh JS, Brown RH, Berry JD. Amyotrophic lateral sclerosis: review. *Semin Neurol.* 2015;35(4):469-476.
4. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. *Lancet.* 2011;377:942-955.
5. Agosta F, Al-Chalabi A, Filippi M, et al. The El Escorial criteria: strengths and weaknesses. *Amyotroph Lateral Scler Frontotemporal Degener.* 2015;16(1-2):1-7.
6. Abe K, Aoki M, Tsuji S, et al. on behalf of the edaravone (MCI-186) ALS 19 study group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. *Lancet Neurol.* 2017;16:505-512.
7. Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. *Amyotroph Lateral Scler Frontotemporal Degener.* 2014;15(7-8):610-617.
8. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). *Neurology.* 2009;73(15):1227-1233.
9. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). *Neurology.* 2009;73:1218-1226.
10. Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. *Eur J Neurol.* 2012;19(3):360-375.
11. Munakata A, Ohkuma H, Nakano T, et al. Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage. *Neurosurgery.* 2009;64(3):423-428.
12. Tsujita K, Shimomura H, Kaikita K, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. *Circ J.* 2006;70(7):832-837.
13. Tang Y, Rong X, Hu W, et al. Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial. *J Neurooncol.* 2014;120(2):441-447.
14. Maeno T, Tano R, Takenaka H, et al. Edaravone (MCI-186) is effective as a free radical scavenger following arteriovenous sheathotomy for treatment of macular edema associated with branch retinal vein occlusion. *Br J Ophthalmol.* 2009;93(11):1479-1482.
15. Sano H, Kamijo T, Ino T, et al. Edaravone, a free radical scavenger, in the treatment of idiopathic sudden sensorineural hearing loss with profound hearing loss. *Auris Nasus Larynx.* 2010;37(1):42-46.
16. Data on file. Radicava™ Product Dossier: Based on AMCP guidelines for formulary submission, version 2.1. MT Pharma America, Inc.; received June 14, 2017.
17. Feng S, Yang Q, Liu M, et al. Edaravone for acute ischaemic stroke. *Cochrane Database Syst Rev.* 2011;12:CD007230.